CFTR and cystic fibrosis: Application of the proteostasis regulator cysteamine and the CK2 inhibitor, epigallocatechin gallate (EGCG) or CX-4945, can reduce the degradation of ∆F508-CFTR, resulting in more mutant channels residing in the membrane, hence alleviation of the symptom of cystic fibrosis patients [79].